A randomized, double-blind, multicenter, phase iii study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

HIGHLIGHTS

  • who: Eun-Seok Jeon from the Changgyeonggungu2011ro, Jongnou2011gu, Seoul, Republic of Korea have published the paper: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy, in the Journal: (JOURNAL) of 17/05/2017
  • what: The aim of this study was to evaluate the efficacy and safety of the fimasartan, amlodipine, and rosuvastatin combination therapy in patients with essential hypertension and dyslipidemia who did not respond adequately to fimasartan . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?